Ballew Advisors, Inc Acelrx Pharmaceuticals Inc Transaction History

Ballew Advisors, Inc

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 12, 2019	SELL	$2.13 - $4.8 $426 - $960	-200 Closed	0 $0
Q3 2018 Oct 30, 2018	BUY	$2.6 - $4.6 $520 - $919	200 New	200 $1,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Ballew Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ballew Advisors, Inc with notifications on news.